Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03330847 | To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy. | active not recruiting | Phase 2 | 273 | AstraZenecaINDUSTRY | 15 | Jul 2, 2026 | clinicaltrials |
| NCT06001762 | TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer | active not recruiting | Phase 2 | 90 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT06500494 | To Describe How Well Vinorelbine Given Orally Works in Patients With a Breast Cancer After 2 Years of Treatment(VINOREAL) | active not recruiting | — | 368 | Pierre Fabre MedicamentINDUSTRY | 3 | Jul 2, 2026 | clinicaltrials |
| NCT07118176 | Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers | active not recruiting | Phase 1 | 30 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT02957968 | Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca | active not recruiting | Phase 2 | 46 | Virginia Commonwealth UniversityOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT03488693 | Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer(TAILOR RT) | active not recruiting | Phase 3 | 2,138 | Canadian Cancer Trials GroupNETWORK | 2 | Jul 1, 2026 | clinicaltrials |
| NCT00582478 | Investigating Mechanisms to Explain Age Associated Differences in Quality of Life Among Breast Cancer Patients | active not recruiting | — | 650 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT03012100 | Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer | active not recruiting | Phase 2 | 280 | Academic and Community Cancer Research UnitedOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT06449222 | Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy | active not recruiting | Phase 2 | 83 | BioNTech SEINDUSTRY | 4 | Jun 30, 2026 | clinicaltrials |
| NCT03032406 | CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer | active not recruiting | Phase 2 | 53 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT06008158 | Evaluation of a Once Per Day Regimen of Accelerated Partial Breast Irradiation for Improved Breast Appearance in Pts w/Low Risk, Hormone Responsive Brst Ca | active not recruiting | Phase 2 | 48 | City of Hope Medical CenterOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT00589654 | Menstrual Cycle Maintenance and Quality of Life: A Prospective Study | active not recruiting | — | 810 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT01273610 | Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer | active not recruiting | Phase 2 | 40 | City of Hope Medical CenterOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT03285230 | The French E3N Prospective Cohort Study(E3N) | active not recruiting | — | 100,000 | Institut National de la Santé Et de la Recherche Médicale, FranceOTHER_GOV | 1 | Jun 25, 2026 | clinicaltrials |
| NCT05082259 | ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab(ASTEROID) | active not recruiting | Phase 1 | 61 | Institute of Cancer Research, United KingdomOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07457541 | Molecular Imaging of Fibroblast Activation Protein Expression Using Labeled Technetium-99m HYNIC-FAPI | active not recruiting | Phase 1 | 15 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT02750358 | Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer | active not recruiting | Phase 2 | 50 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT02764541 | Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS) | active not recruiting | Phase 2 | 195 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT04414202 | Observational Study of Intra-operative Partial Irradiation of Invasive Ductal Breast Carcinomas With a Good Prognosis(INTRA-OBS) | active not recruiting | — | 519 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT05323955 | Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib(BRIDGET) | active not recruiting | Phase 2 | 48 | Carey Anders, M.D.OTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT05942092 | ROLL Versus Magnetic Seed for Preoperative Localization of Non-palpable Breast Lesion: Comparison Between Techniques.(SEED01) | active not recruiting | — | 1,400 | Istituti Clinici Scientifici Maugeri SpAOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT05942118 | Comparison Between ROLL Versus Magnetic Seed for Preoperative Localization of Non-palpable Breast Lesion by Randomized Clinical Study.(SEED02) | active not recruiting | — | 262 | Istituti Clinici Scientifici Maugeri SpAOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT04188548 | A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer(EMBER) | active not recruiting | Phase 1 | 379 | Eli Lilly and CompanyINDUSTRY | 8 | Jun 22, 2026 | clinicaltrials |
| NCT05143970 | A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors(CHANCES) | active not recruiting | Phase 1 | 27 | Institut Paoli-CalmettesOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT04308720 | Circulating Tumor DNA and Immunophenotyping as Potential Biomarkers With Regional Nodal Irradiation for Breast Cancer | active not recruiting | — | 217 | Mayo ClinicOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT04616248 | In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors | active not recruiting | Phase 1 | 14 | University of Southern CaliforniaOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT06257264 | A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors | active not recruiting | Phase 1 | 103 | BeiGeneINDUSTRY | 6 | Jun 18, 2026 | clinicaltrials |
| NCT01791829 | A Prospective Cohort Study Evaluating Risk of Local Recurrence Following Breast Conserving Surgery and Endocrine Therapy in Low Risk Luminal A Breast Cancer(LUMINA) | active not recruiting | — | 500 | Ontario Clinical Oncology Group (OCOG)OTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT03362060 | PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer | active not recruiting | Phase 1 | 20 | Massachusetts General HospitalOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT03945721 | A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients(UNITY) | active not recruiting | Phase 1 | 21 | Massachusetts General HospitalOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT04228991 | Hypofractionated LocoRegional Radiotherapy in Breast Cancer(RHEAL) | active not recruiting | Phase 3 | 588 | Ontario Clinical Oncology Group (OCOG)OTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT04298086 | A Study of the Body's Response to Exercise and a Plant-Based Diet in Overweight Postmenopausal Women With Breast Cancer | active not recruiting | Phase 2 | 43 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT04837209 | Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer(NADiR) | active not recruiting | Phase 2 | 32 | Massachusetts General HospitalOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT04961996 | A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) | active not recruiting | Phase 3 | 4,170 | Hoffmann-La RocheINDUSTRY | 54 | Jun 17, 2026 | clinicaltrials |
| NCT07092254 | Patterns of Care and Outcomes in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer | active not recruiting | — | 760 | Daiichi SankyoINDUSTRY | 1 | Jun 17, 2026 | clinicaltrials |
| NCT04796220 | Focused Ultrasound and Gemcitabine in Breast Cancer(Breast 54) | active not recruiting | Phase 1 | 32 | Patrick Dillon, MDOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT04928261 | Evaluating 6-months of HER2-targeted Therapy in Patients With HER2 Positive Early-stage Breast Cancer That Achieve a Pathological Complete Response to Neoadjuvant Systemic Therapy | active not recruiting | Phase 4 | 52 | Ottawa Hospital Research InstituteOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT01504789 | Part II: Exercise in Hispanic Breast Cancer Survivors | active not recruiting | N/A | 53 | M.D. Anderson Cancer CenterOTHER | 2 | Jun 15, 2026 | clinicaltrials |
| NCT02513394 | PALbociclib CoLlaborative Adjuvant Study(PALLAS) | active not recruiting | Phase 3 | 5,796 | Alliance Foundation Trials, LLC.OTHER | 21 | Jun 15, 2026 | clinicaltrials |
| NCT02515110 | Hypofractionated Regional Nodal Irradiation Clinical Trial for Women With Breast Cancer | active not recruiting | N/A | 137 | Virginia Commonwealth UniversityOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT04457596 | T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial | active not recruiting | Phase 3 | 1,056 | Alliance for Clinical Trials in OncologyOTHER | 3 | Jun 15, 2026 | clinicaltrials |
| NCT05629585 | A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03) | active not recruiting | Phase 3 | 1,174 | AstraZenecaINDUSTRY | 17 | Jun 15, 2026 | clinicaltrials |
| NCT00929214 | Aggressive Local Therapy for Limited Bone-Only Metastasis to Improve Progression-Free Survival in Breast Cancer Patients | active not recruiting | Phase 2 | 35 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04421963 | Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib(ROSY-O) | active not recruiting | Phase 3 | 185 | AstraZenecaINDUSTRY | 23 | Jun 12, 2026 | clinicaltrials |
| NCT05132296 | Mobile-Health Delivery of Lifestyle Interventions for Women With Breast Cancer | active not recruiting | N/A | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05226663 | A Radiotracer ([18F]FluorThanatrace) by PET/CT for the Imaging of Breast Cancer | active not recruiting | Phase 2 | 36 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05563220 | Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer(ELEVATE) | active not recruiting | Phase 1 / Phase 2 | 435 | Stemline Therapeutics, Inc.INDUSTRY | 13 | Jun 12, 2026 | clinicaltrials |
| NCT02079662 | The Role of Lifestyle Factors in Breast Cancer-Related Outcomes | active not recruiting | N/A | 110 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 2, 2026source: clinicaltrials